A Phase I Study Using Most Closely HLA-matched Adenovirus-specific T Lymphocytes for the Treatment of Adenovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-A)

Trial Profile

A Phase I Study Using Most Closely HLA-matched Adenovirus-specific T Lymphocytes for the Treatment of Adenovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-A)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Adenovirus specific T cells ViraCyte (Primary)
  • Indications Adenovirus infections
  • Focus Adverse reactions
  • Acronyms VIRALYM-A
  • Sponsors ViraCyte
  • Most Recent Events

    • 27 Jul 2017 Planned initiation date changed from 1 Aug 2017 to 1 Sep 2017.
    • 24 Jul 2017 Planned initiation date changed from 1 Jan 2016 to 1 Aug 2017.
    • 21 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top